help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schilsky, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schilsky, R. L.
The Oncologist, Vol. 1, No. 4, 244–247, August 1996
© 1996 AlphaMed Press


ADVANCES IN CANCER TREATMENT: THE CHABNER SYMPOSIUM

Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era

Richard L. Schilsky

Section of Hematology-Oncology, Department of Medicine, Committee on Clinical Pharmacology and the Cancer Research Center, University of Chicago, Chicago, Illinois, USA

Correspondence: Richard L. Schilsky, M.D., University of Chicago, Cancer Research Center, 5841 South Maryland Avenue, AMB O-119, MC 1140, Chicago, IL 60637, USA. Telephone: 312-702-6180; Fax: 312-702-9311.

This paper chronicles developments in the laboratory of Dr. Bruce Chabner during the period 1978-1981. Initial work demonstrated that methotrexate is taken up by human breast cancer cells by a high-affinity, carrier-mediated, energy-dependent transport system similar to that described in murine leukemia cells. Conversion of methotrexate to a high molecular weight polyglutamate metabolite was also demonstrated to occur in human breast cancer cells. Polyglutamates became the predominant form of intracellular drug, both free in the cytosol and bound to dihydrofolate reductase, during a 24 h exposure to clinically achievable methotrexate concentrations. Intracellular retention of polyglutamates led to prolonged suppression of thymidine synthesis and loss of cell viability after removal of extracellular drug. This work identified methotrexate polyglutamates as biologically active enzyme inhibitors in human tumor cells and launched a series of investigations on the interaction of these derivatives with folate-requiring enzymes.

Key Words. Methotrexate • Polyglutamate • Leucovorin • Stereoisomers • 5-fluorouracil • 5-ethynyluracil







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 1996 by AlphaMed Press.